Different somatic alterations of the *HRPT2* gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an *HRPT2* germline mutation

F Cetani¹, E Pardi¹, E Ambrogini¹, P Viacava², S Borsari¹, M Lemmi¹, L Cianferotti¹, P Miccoli³, A Pinchera¹, A Arnold⁴ and C Marcocci¹

Departments of ¹Endocrinology and Metabolism, ²Oncology, Section of Pathology and ³Surgery, University of Pise, Pise, Italy
⁴Center for Molecular Medicine and Division of Endocrinology & Metabolism, University of Connecticut School of Medicine, Farmington, Connecticut, USA

(Requests for offprints should be addressed to F Cetani; Email: cetani@endoc.med.unipi.it)

Abstract

Early onset of primary hyperparathyroidism (PHPT) and multiglandular involvement suggest a familial form in which germline mutation of a *PHPT*-related gene(s) and a somatic event at the same locus can be often demonstrated. We investigated the involvement of multiple endocrine neoplasia type 1 (*MEN1*) and *HRPT2* genes in a 39-year-old man with recurrent PHPT. PHPT was firstly diagnosed at the age of 21 and the patient had two recurrences separated by extended periods of normocalcemia. This unusual history prompted us to investigate other family members and study the *MEN1* and *HRPT2* genes. An *HRPT2* germline missense mutation in exon 3 (R91P) was found in the index case, which was associated with different *HRPT2* somatic alterations in each of the three examined parathyroid tumors. These findings are consistent with Knudson's 'two hit' concept of biallelic inactivation of classical tumor suppressor genes. Screening of 15 asymptomatic relatives was negative for the R91P germline mutation. All the three abnormal parathyroid specimens showed cystic features at histology and were negative for parafibromin immunostaining. In one specimen, diffuse parafibromin staining was evident in a rim of normal parathyroid tissue surrounding the adenomatous lesion. Our study shows that different somatic genetic events at the *HRPT2* locus are responsible for the asynchronous occurrence of multiple adenomas in a patient carrying an *HRPT2* germline mutation. The finding of diffuse parafibromin staining in a rim of normal parathyroid tissue, but not in the contiguous adenomatous lesion, reinforces the concept that loss of parafibromin expression is responsible for the development of parathyroid tumors in this setting.

Endocrine-Related Cancer (2007) 14 493–499

Introduction

Primary hyperparathyroidism (PHPT) is one of the most common endocrine disorders, especially in postmenopausal women in whom it reaches a prevalence of 2–3% (Adami *et al.* 2002). A single, benign parathyroid adenoma is responsible for sporadic PHPT in 80–85% of cases, the remaining being caused by multiple adenomas, hyperplasia of all parathyroid glands, and rarely by carcinoma (Marx 2000). On the other hand, multiglandular involvement is typically found in familial forms of PHPT, namely multiple endocrine neoplasia

types 1 and 2A (MEN 1 and MEN 2A), hyperparathyroidism–jaw tumor syndrome (HPT–JT), or familial isolated hyperparathyroidism (FIHP) (Marx *et al.* 2002). These inherited forms of PHPT typically present at an earlier age than sporadic forms of PHPT and occur with equal frequencies in both sexes. Thus, the finding of multiglandular involvement at surgery or recurrence of PHPT in the same individual, particularly in a young subject, could suggest a hereditary syndrome.

The identification of genes responsible for familial PHPT (*MEN1*, *HRPT2*, *CASR*, and *RET* genes) has

increased our knowledge about parathyroid tumorigenesis (Chandrasekharappa *et al.* 1997, Carpten *et al.* 2002, Marx *et al.* 2002). *MEN1* and *HRPT2* function as tumor suppressor genes, consistent with the Knudson 'two hit' hypothesis. The second hit often causes loss of heterozygosity (LOH) of a large chromosomal region, as in the majority (~70–90%) of *MEN1*-associated tumors (Larsson *et al.* 1988, Friedman *et al.* 1989, Thakker *et al.* 1989, Pannett & Thakker 2001), but other mechanisms such as smaller deletions and point mutations that may also inactivate the gene, can occur and seem to be preferentially involved in *HRPT2*-related tumors (~30–50%; Arnold *et al.* 2002, Carpten *et al.* 2002, Howell *et al.* 2003, Shattuck *et al.* 2003, Cetani *et al.* 2004, Villablanca *et al.* 2004, Moon *et al.* 2005, Bradley *et al.* 2006, Kelly *et al.* 2006, Mizusawa *et al.* 2006). Hereditary syndrome when compared with sporadic parathyroid tumors shows early onset age and multiplicity, because each parathyroid cell has 'one hit' by inheritance. Thus, subtotal or total parathyroidectomy is usually performed for the cure of familial PHPT, whereas the excision of the single diseased gland is sufficient in most cases of sporadic PHPT.

In this report, we describe a 39-year-old man with sporadic PHPT, who had two recurrences after successful surgery over a 17-year follow-up. This unusual history prompted us to perform genetic studies, which led to the identification of a *HRPT2* germline mutation associated with independent *HRPT2* somatic alterations (mutations or LOH at the same locus) in the different parathyroid tumors.

Materials and methods

Case report

The proband, a 39-year-old man, referred to our Department in February 1998 for recurrent sporadic PHPT. In 1987, at the age of 21 years, a severe form of PHPT was diagnosed (serum calcium 17.3 mg/dl (normal range 8.2–10.2); C-PTH 3.17 ng/ml (< 0.88 ng/ml), and *osteitis fibrosa cystica*). On surgery, a 3-cm right inferior (RI) parathyroid gland was removed. Three additional parathyroid glands were identified and showed a normal appearance; a biopsy of the left superior (LS) parathyroid was carried out. Histological examination showed a RI parathyroid adenoma and normal parathyroid tissue of the LS gland. Three years later, in 1990, recurrence of PHPT was documented but no treatment was advised. In 1993, the patient underwent cervical exploration and a 1.5 cm right superior (RS) parathyroid gland was

excised and both left glands appeared grossly normal. Histology revealed an oxyphilic adenoma. Serum calcium and PTH remained normal until 1997 when a further recurrence of PHPT was documented and the patient referred to our department. The patient was in good health. Serum calcium and PTH were mildly elevated (10.6 mg/dl and 72 pg/ml (normal range 10–65) respectively). There was no evidence of *MEN1*-associated neoplasia. No kidney lesions or jaw tumor were detected. Parathyroidectomy was advised, but the patient was lost to follow-up until 2004, when he was referred again to our department. The patient was in good general condition. No cutaneous lesions were evident at physical examination. Serum total and ionized calcium (12.2 mg/dl (2.70 mmol/l) and 5.5 mg/dl (1.75 mmol/l) respectively), PTH (260 pg/ml), and markers of bone turnover were elevated. Prolactin (PRL), growth hormone (GH), insulin-like growth factor-I (IGF-I), thyroid-stimulating hormone (TSH), adrenocorticotrophic hormone (ACTH), cortisol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), insulin, gastrin, vasoactive intestinal polypeptide (VIP), glucagon, serotonin, adrenalin, noradrenalin and glucose concentrations were within the normal range. Neck imaging studies (ultrasound, 99m-Tc-sestamibi scan and computerized tomography (CT)) showed two enlarged parathyroids in the left side of the neck. No pancreatic or adrenal lesions were found by ultrasound or CT. Chest X-ray and CT were normal. Orthopantomography of the jaw was negative. The patient was submitted to surgery with removal of the LS (1.5 cm) and left inferior (LI; 1.0 cm) parathyroid glands. Histological examination showed chief cell adenomas. After a transient hypocalcemia, serum calcium and PTH remained normal until March 2006.

Fifteen first degree relatives were available for further investigations. Serum calcium and PTH were in the normal range in all cases.

Informed consent was obtained from the patient and his relatives for all procedures used in the present study. The study was approved by the local ethical committee.

Methods

Tissue samples

Tissues were obtained at the time of surgery, immediately snap frozen in liquid nitrogen and stored at –80 °C until use. Tissue sample of the RI parathyroid gland was not available.

Genetic studies

Genomic DNA was isolated from peripheral blood leukocytes and parathyroid tissues by the standard proteinase K-SDS digestion and the phenol/chloroform method. Allelic deletions and direct sequencing of *HRPT2* and *MEN1* genes were assessed in both blood leukocytes and tumor DNAs as described previously (Cetani *et al.* 2004). Nucleotide sequences were determined on double strands at least twice. The intragenic polymorphisms in introns 10 and 14 of the *HRPT2* gene and the microsatellite markers (PYGM and D11S449) flanking the *MEN1* gene were used. The region of interest of the *HRPT2* gene was also amplified using constitutional DNA of all family members and 55 unrelated controls of Italian origin (110 chromosomes). The sequence abnormality found in the constitutional DNA was confirmed by restriction enzyme analysis.

Immunohistochemistry

Sections of the left parathyroid tumors were deparaffinized in xylene and rehydrated in alcohol. Endogenous peroxidase activity was blocked by incubating the slides in 1% hydrogen peroxide in methanol for 10 min. In order to unmask the antigen, the slides were microwave-treated in 10 mM citrate buffer, pH 6.0 for 10 min. After blocking nonspecific staining with normal serum, the sections were incubated for 1 h with the primary anti-parafibromin monoclonal antibody (Tan *et al.* 2004; kindly donated by Bin Tean Teh), which was used at 1:50 dilution. This antibody is directed against the portion of the protein corresponding to amino acid positions 87–100. The sections were then incubated with biotin-labeled secondary antibody (dilution 1:500) and avidin–biotin complex (Vector Laboratories, Burlingame, CA, USA) for 30 min each. Sites of binding were visualized using 3,3-diaminobenzidine as chromogen. Finally, sections were counterstained with hematoxylin, dehydrated, and mounted. The positive control was normal parathyroid and two negative controls included experiments omitting primary antibody or using primary antibody pre-absorbed with a 20-fold excess of the immunizing peptide. For each case, six different sections were analyzed.

Tumors were scored as positive if specific nuclear staining was detected and the staining was quantified according to the percentage of positive cells, independently of the intensity of staining (Cetani *et al.* 2007). Tumors were scored as negative when no tumor cells showed a specific nuclear staining.

Results

Genetic studies

All tissue specimens were heterozygous for the *MEN1* gene flanking markers *D11S449* and *PYGM*, thus indicating the absence of large chromosomal deletions. Direct sequencing of the *MEN1* gene did not reveal any mutation.

Results of *HRPT2* gene are summarized in Table 1 and shown in Fig. 1. LOH of both intragenic markers was identified in the LS parathyroid specimens. Retained heterozygosity was present in the other parathyroid samples. Sequence analysis of PCR-amplified tumor and germline DNAs revealed two missense (R91P and A2S) and one nonsense (Y54X) *HRPT2* mutations. The R91P mutation was germline; the A2S mutation was found only in the LI gland, and the Y54X only in the RS. The latter mutation has been previously reported in a parathyroid cancer (Howell *et al.* 2003, Shattuck *et al.* 2003). The two missense mutations alter evolutionarily conserved amino acids (alanine to a serine and arginine to a proline). The substitution of the nonpolar hydrophobic alanine for a polar hydrophilic serine in the A2S mutation and of an arginine for a helix-breaker proline in the R91P mutation may likely lead to deleterious structural alterations of parafibromin that may affect its function.

The R91P germline mutation led to the loss of a *TaqI* site providing a convenient diagnostic test to confirm the presence of mutation in the proband and to demonstrate its absence in the other family members and 55 control DNAs. As indicated in Fig. 1, digestion of a fragment of exon 3 containing the R91P mutation with *TaqI* produced a 163 (mutant allele), 85 and 78 bp (wild-type allele) fragments. All relatives were also screened for the mutation by sequencing. The R91P mutation was absent in the patient's mother and sister and in three paternal first-degree cousins. We could not investigate the father because he was deceased, but the paternal grandfather

Table 1 Genetic studies in parathyroid tissues

Parathyroid gland	<i>HRPT2</i> sequence	LOH <i>HRPT2</i> locus ^a
Right inferior	NA	NA ^b
Right superior	Y54X Somatic R91P Germline	Retention
Left inferior	A2S Somatic R91P Germline	Retention
Left superior	R91P Germline	LOH

^aIntragenic markers in introns 10 and 14 were studied (Shattuck *et al.* 2003).

^bNot available.

Figure 1 Mutational analysis, LOH, and restriction enzyme analyses of *HRPT2* gene. (A) Sequencing chromatograms. Left panel: heterozygous R91P germline mutation in exon 3 (CGA>CCA); middle panel: heterozygous Y54X somatic mutation detected in the RS adenoma (TAC>TAG); right panel: heterozygous A2S somatic mutation detected in the LI adenoma (GCG>TCG). (B) LOH analysis. Tumor DNA shows a LOH (arrow) using intron 10 polymorphism. (C) Detection of a R91P mutation in exon 3 by restriction endonuclease analysis. The mutation results in the loss of a *TaqI* restriction enzyme site. Following PCR with appropriate primers of a fragment of exon 3 and cleavage with *TaqI*, a band of 163 bp (mutant allele) and two bands of 85 and 78 bp are shown in the patient (lane 1) and only the latter bands in the control subject (lane 2). The positions of the size markers at 100 and 200 bp are indicated.

and all the father's six siblings were negative. These data suggest that the R91P germline mutation occurred *de novo* in our patient. This mutation was not detected in the patient's three sons.

Immunohistochemistry

Normal parathyroid gland was used as the positive control and showed a diffuse nuclear staining in ~90% of chief cells, without staining of adipose and connective tissue or blood vessels. All abnormal parathyroid specimens showed cystic features and were negative for parafibromin expression (Fig. 2). Interestingly, parafibromin staining was retained in a rim of normal parathyroid tissue surrounding the LI adenoma. The percentage of positive cells and the intensity of staining were comparable to those observed in the normal parathyroid gland.

Discussion

The medical history and the apparent success of initial surgery (RI parathyroidectomy) were consistent with the diagnosis of sporadic PHPT due to a single parathyroid adenoma, but the subsequent follow-up has clearly shown that this was not the case. Indeed, the patient had two recurrences of PHPT, which occurred 3 and 4 years after normalization of serum calcium and PTH, in both cases following the excision of a single enlarged

parathyroid gland, with a histological picture of adenoma. Moreover, in both occasions, evidence of histologically normal parathyroid tissue was available. Thus, after the second adenomectomy, which was followed by normocalcemia, it was reasonable to believe that the patient was affected by double parathyroid adenomas. However, as mentioned before, a further relapse of PHPT occurred and, at this time, two enlarged parathyroid glands were removed and chief cell adenomas were found at histology.

The early presentation of PHPT and the evidence of subsequent multiglandular involvement, despite the absence of family history and other associated syndromic manifestations, suggested a possible hereditary form of PHPT. We studied the *MEN1* and *HRPT2* genes, although we would not have had as high an expectation for *MEN1*, since the asynchrony, the 'one adenoma at a time' presentation and the presence of cystic changes in parathyroid tumors suggest the involvement of the *HRPT2* gene rather than the *MEN1* gene. We found a *HRPT2* germline mutation, which was paired with different acquired genetic abnormalities in the three abnormal parathyroid glands we studied. Interestingly, the *HRPT2* germline mutation was missense. Nonsense or frameshift mutations, resulting in truncated proteins, usually occur in the HPT-JT syndrome and parathyroid cancer (Carpten et al. 2002, Howell et al. 2003, Shattuck et al.

Figure 2 Histology (upper panels) and parafibromin staining (lower panels). (A) The adenomatous tissue and a rim of normal tissue separated by the capsule are shown (LI parathyroid adenoma, hematoxylin-eosin, $\times 100$). (B) Large cystic lesion of LI parathyroid adenoma (hematoxylin-eosin, $\times 100$). (C) Multiple cystic lesions of LS parathyroid adenoma (hematoxylin-eosin, $\times 100$). (D) Low magnification of the LI parathyroid adenoma showing a rim of normal parathyroid tissue (immunohistochemistry, $\times 40$). (E) Magnification of inset 1 of panel D showing a diffuse nuclear immunoreactivity of normal parathyroid tissue surrounding the adenoma (immunohistochemistry, $\times 400$). (F) Magnification of inset 2 of panel D showing absence of nuclear immunoreactivity of adenomatous tissue (immunohistochemistry, $\times 400$). (G) Normal parathyroid gland showing a diffuse nuclear immunoreactivity (immunohistochemistry, $\times 200$).

2003, Cetani *et al.* 2004, Bradley *et al.* 2006). It has been hypothesized that missense mutations, resulting in abnormal proteins, may have a lower phenotypic penetrance. As a matter of fact, an association between *MEN1* gene missense mutations and FIHP has been reported by Pannett & Thakker (2001). A similar *HRPT2* mutation spectrum has been suggested in FIHP versus HPT–JT (Carpten *et al.* 2002, Howell *et al.* 2003, Cetani *et al.* 2004, Simonds *et al.* 2004, Villablanca *et al.* 2004, Bradley *et al.* 2005a,b, 2006, Guarnieri *et al.* 2006, Kelly *et al.* 2006, Mizusawa *et al.* 2006) reveals that 16.7% are missense mutations as opposed to 9.5% in HPT–JT (Carpten *et al.* 2002, Howell *et al.* 2003, Bradley *et al.* 2005b, 2006, Moon *et al.* 2005, Aldred *et al.* 2006, Mizusawa *et al.* 2006, Yamashita *et al.* 2007). Thus, the presence of a missense mutation might explain the absence of an obvious family history in apparently sporadic PHPT patients. This is in keeping with the findings in our patient, in whom, despite the R91P germinal *HRPT2* mutation, no other phenotypic features of classical HPT–JT were present. On the other hand, this mutation might have increased parathyroid proliferation and therefore the risk of additional somatic events, responsible for the

asynchronous development of parathyroid gland abnormalities in our patient. Indeed, different *HRPT2* gene somatic alterations were found in each individual excised gland. Asynchronous somatic events may account for the usual clinical history of recurrent PHPT in HPT–JT, in which each recurrence occurs as a single gland disease, separated by periods of normocalcemia. The importance of a second somatic hit at the *HRPT2* locus in the pathogenesis of parathyroid adenomas in our patient is strongly supported by the finding of positive parafibromin staining in a small rim of normal tissue surrounding the LI adenoma.

Only one study has investigated genetic alterations in multiple tumors occurring in the same patient with sporadic PHPT (five cases of double adenomas; Dwight *et al.* 2002). The tumors were examined for LOH at distal 1p, HPT–JT locus at 1q-21-32 and flanking regions, and *MEN1* locus at 11q13. Different genetic events were found in paired glands. While LOH was found in one gland, the other gland showed either LOH in another locus or no allelic loss. In particular, three tumors had LOH at 11q13 associated with a somatic *MEN1* mutation in the other allele, but not in the germline DNA.

The *HRPT2* germline mutation found in the present study involves amino acid 91 and, therefore, it is possible that the anti-parafibromin antibody used in the present study, which is directed against amino acids 87–100, may

not recognize the protein encoded by the germline mutated *HRPT2* allele. Thus, the absence of parafibromin staining would not demonstrate its inactivation in the tumor. On the other hand, the replacement of an arginine for a helix-breaker proline suggests parafibromin inactivation.

Our patient had removed four abnormal parathyroid glands, which were asynchronously involved over a 17-year period. The normal serum calcium and PTH after the last surgical procedure suggest the presence of supernumerary parathyroid gland(s). Alternatively, it is possible that the patient has a small amount of locally invasive parathyroid cancer in the right side of the neck, which was not re-explored at the last surgery, or metastatic disease elsewhere. Re-evaluation of all histological sections of right-side tumors by our pathologist (PV) showed no histologic features suggestive of potential malignancy. Since *HRPT2* mutation carriers are at risk for recurrence of PHPT or parathyroid cancer, regular follow-up is mandatory in our patient. Frequent surveillance may allow an early detection and cure of PHPT, before a possible development of malignancy (Guarnieri et al. 2006, Kelly et al. 2006).

In conclusion, our study shows that different somatic genetic events at the *HRPT2* locus are associated with the asynchronous occurrence of multiple adenomas in a patient carrying an *HRPT2* germline mutation. The finding of diffuse parafibromin staining in a rim of normal parathyroid tissue, but not in the adenomatous lesion, further reinforces the concept that loss of parafibromin expression is responsible for the development of such parathyroid tumors.

Acknowledgements

This work was supported by Grants from the University of Pisa (Fondi di Ateneo per la Ricerca) and the Ministero dell'Istruzione, dell'Università e della Ricerca (Project: Studies of new oncongenes involved in parathyroid tumorigenesis), and the Murray-Heilig Fund in Molecular Medicine (AA). We would like to thank the family that graciously agreed to participate in the study and Prof. Bin Tean Teh, Van Andel Research Institute, Grand Rapids, Michigan, USA, for the generous gift of the monoclonal parafibromin antibody and Pasquale Cofelice for his technical assistance. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

- Adami S, Marcocci C & Gatti D 2002 Epidemiology of primary hyperparathyroidism in Europe. *Journal of Bone and Mineral Research* **17** (Suppl 2) N18–N23.
- Aldred MJ, Talacko AA, Savarirayan R, Murdolo V, Mills AE, Radden BG, Alimov A, Villablanca A & Larsson C 2006 Dental findings in a family with hyperparathyroidism–jaw tumor syndrome and a novel *HRPT2* gene mutation. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics* **101** 212–218.
- Arnold A, Shattuck TM, Mallya AM, Krebs LJ, Costa J, Gallacher J, Wild Y & Saucier K 2002 Molecular pathogenesis of primary hyperparathyroidism. *Journal of Bone and Mineral Research* **17** (Suppl 2) N30–N36.
- Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE, Laidler T, Manek S, Robbins CM, Salti IS et al. 2005a Uterine tumors are a phenotypic manifestation of the hyperparathyroidism–jaw tumor syndrome. *Journal of Internal Medicine* **257** 18–26.
- Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A & Thakker RV 2005b Utilisation of a cryptic non-canonical donor splice site of the gene encoding *PARAFIBROMIN* is associated with familial isolated primary hyperparathyroidism. *Journal of Medical Genetics* **42** e51.
- Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, Fratter C, Besser GM, Conceicao Pereira M, Davie MW, Dudley N et al. 2006 Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. *Clinical Endocrinology* **64** 299–306.
- Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciutti S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD et al. 2002 *HRPT2*, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumors syndrome. *Nature Genetics* **32** 676–680.
- Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzero E, Colussi G, Berti P et al. 2004 Genetic analyses of the *HRPT2* gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. *Journal of Clinical Endocrinology and Metabolism* **89** 5583–5591.
- Cetani F, Ambrogini E, Vacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P et al. 2007 Should parafibromin staining replace *HRPT2* gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? *European Journal of Endocrinology* **156** 547–554.
- Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang ZP, Lubenski IA, Liotta LA et al. 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. *Science* **276** 404–407.
- Dwight T, Nelson AE, Theodosopoulos G, Richardson AL, Learoyd DL, Philips J, Delbridge L, Zedenius J, Teh BT, Larsson C et al. 2002 Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. *American Journal of Pathology* **161** 1299–1306.
- Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering MB, Weinstein LS, McBride WO, Nakamura Y,

- Brandi ML *et al.* 1989 Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. *New England Journal of Medicine* **321** 213–218.
- Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M, Minisola S, Mascia ML, D'Agruma L & Cole DE 2006 Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with *HRPT2* mutation: implications for cancer surveillance. *Journal of Clinical Endocrinology and Metabolism* **91** 2827–2832.
- Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J *et al.* 2003 *HRPT2* mutations are associated with malignancy in sporadic parathyroid tumors. *Journal of Medical Genetics* **40** 657–663.
- Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R, Arnold A & Carpenter TO 2006 Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline *HRPT2* mutation. *Journal of Bone and Mineral Research* **21** 1666–1671.
- Larsson C, Skogseid B, Oberg K, Nakamura Y & Nordenskold M 1988 Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. *Nature* **332** 85–87.
- Marx SJ 2000 Hyperparathyroidism and hypoparathyroidism disorders. *New England Journal of Medicine* **343** 1863–1875.
- Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander HR Jr *et al.* 2002 Hyperparathyroidism in hereditary syndromes: special expressions and special managements. *Journal of Bone and Mineral Research* **17** (Suppl 2) N37–N43.
- Mizusawa N, Uchino S, Iwata T, Tsuyuguchi M, Suzuki Y, Mizukoshi T, Yamashita Y, Sakurai A, Suzuki S, Beniko M *et al.* 2006 Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism–jaw tumour syndrome. *Clinical Endocrinology* **65** 9–16.
- Moon SD, Park JH, Kim EM, Kim JH, Han JH, Yoo SJ, Yoon KH, Kang MI, Lee KW, Son HY *et al.* 2005 A novel IVS2-1G>A mutation causes aberrant splicing of the *HRPT2* gene in a family with hyperparathyroidism–jaw tumor syndrome. *Journal of Clinical Endocrinology and Metabolism* **90** 878–883.
- Pannett AA & Thakker RV 2001 Somatic mutations in MEN type 1 tumors, consistent with the Knudson ‘two-hit’ hypothesis. *Journal of Clinical Endocrinology and Metabolism* **86** 4371–4374.
- Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD *et al.* 2003 Somatic and germ-line mutations of the *HRPT2* gene in sporadic parathyroid Carcinoma. *New England Journal of Medicine* **349** 1722–1729.
- Simonds WF, Robbinc CM, Agarwal SK, Hendy GN, Carpten JD & Marx SJ 2004 Familial isolated hyperparathyroidism is rarely caused by germline mutations in *HRPT2*, the gene for the hyperparathyroidism–jaw tumor syndrome. *Journal of Clinical Endocrinology and Metabolism* **89** 96–102.
- Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR *et al.* 2004 Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. *Clinical Cancer Research* **10** 6629–6637.
- Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, Besser GM & O’Riordan JL 1989 Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. *New England Journal of Medicine* **321** 218–224.
- Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, Petillo D, Bateurs C, Kahnoski K, Ebeling T, Salmela P *et al.* 2004 Germline and *de novo* mutations in the *HRPT2* tumor suppressor gene in familial isolated hyperparathyroidism (FIHP). *Journal of Medical Genetics* **41** e32.
- Yamashita Y, Akiyama T, Mizusawa N, Yoshimoto K & Goto M 2007 A case of hyperparathyroidism–jaw tumor syndrome found in the treatment of an ossifying fibroma in the maxillary bone. *International Journal of Oral and Maxillofacial Surgery* **36** 365–369.